INTRODUCTION
The standard treatment approach in patients with newly diagnosed multiple myeloma (MM) who are candidates for auto-SCT includes induction therapy with 3-6 cycles of a nonalkylator-containing regimen followed by auto-SCT. This latter procedure involves stem cell (SC) mobilization and collection followed by the administration of high-dose chemotherapy and autologous SC infusion. Until recently, the most commonly used induction regimen for these patients was the combination of vincristine, doxorubicin and dexamethasone. 1 In the past decade, advances in the treatment of MM have led to the incorporation of novel agents-immunomodulators and proteasome inhibitors-in the induction regimens such as thalidomide, lenalidomide and bortezomib. This approach has resulted in higher response rates following induction therapy and auto-SCT. 2, 3 Previous studies have determined that the optimal number of CD34 þ cells for a single auto-SCT is 4-6 Â 10 6 CD34 þ cells/kg, with deleterious effects on engraftment observed once the SC dose falls below 2 Â 10 6 CD34 þ cells/kg. 4 ,5 G-CSF with or without chemotherapy is considered the standard approach for SC mobilization. Advances in mobilization strategies include the combination of plerixafor and G-CSF, which was shown to enhance the collection of CD34 þ cells compared with G-CSF alone. 6 Despite these advances in SC collection strategies, it is estimated that about 5% of patients with MM fail to mobilize sufficient SCs for auto-SCT. 3 Risk factors associated with poor SC yield and mobilization failure include age, exposure to alkylating agents such as melphalan, extensive radiation therapy, widespread BM infiltration and mobilization regimens. [7] [8] [9] [10] [11] [12] With the increasing use of novel agents in the upfront setting, several reports have emerged raising concerns regarding their impact on the ability to adequately collect SCs. Hence, the number of patients failing SC collection may have increased in patients who receive newer agents, especially lenalidomide. [13] [14] [15] [16] [17] Similarly, the controversy regarding the effect of thalidomide on SC collection and engraftment persists with studies showing discordant results. [18] [19] [20] [21] The inability to collect sufficient CD34 þ cells to proceed to transplantation is concerning, as this would preclude a patient from receiving one of the most effective treatments in MM.
This retrospective study examines the impact of novel therapies on SC mobilization auto-SCT in a cohort of patients with MM treated at Memorial Sloan-Kettering Cancer Center (MSKCC). The primary objective was to determine the rate of SC mobilization failure in patients treated with novel agents administered alone or in combinations and identify risk factors associated with mobilization failure. The secondary objective included the analysis of SC collection efficiency and identifying any associated risk factors.
PATIENTS AND METHODS

Patient population
This retrospective study included all adult patients with MM referred for SC collection at MSKCC between January 2000 and December 2009 who proceeded with a SC collection attempt. They all received induction therapy with various combinations including thalidomide, lenalidomide or bortezomib-based regimens or other combinations of chemotherapy before the introduction of novel agents. The patients were categorized into four groups according to the induction regimen including those who received a combination containing thalidomide (group 1), lenalidomide (group 2), bortezomib (group 3) or none of the above (group 4). Groups 1, 2 and 3 overlapped, as some patients received more than one novel agent for induction treatment. Patients who received mobilization regimens other than single-agent G-CSF or cyclophosphamide plus G-CSF were excluded from the study. Waiver of authorization and waiver of informed consent were granted by the Institutional Review Board.
Retrospective data collection
The patients' baseline and treatment characteristics were obtained from the pharmacy data base and electronic medical record. Baseline characteristics examined included the following: patients' demographics; disease isotype; staging according to the International Staging System; BM plasmacytosis as determined by manual cell count of a BM aspirate before SC collection; WBC and platelet count before SC collection; and risk assessment by cytogenetics using karyotyping and FISH analyses. The patients were classified into risk categories according to the Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) classification. 22 Treatment characteristics included the following: type of drug received during induction therapy; previous radiation exposure before SC collection, as it has previously been associated with SC collection failure; time from initiation of therapy to SC collection; time from diagnosis to SC collection; time from end of induction treatment to SC collection; number of cycles received; and SC mobilization strategy, namely cyclophosphamide ± G-CSF.
All collections were performed on a COBE SPECTRA blood cell separator. A total of 15 L of whole blood was processed and the patients were not collected unless their pre procedure WBC was 5 Â 10 3 /mL. The number of procedures ranged from 1 to 5.
Statistical analysis
The goal of the study was to identify factors that impact mobilization and more specifically, to determine the effects of novel therapies on the efficiency of SC collection. The primary endpoint was the rate of SC collection failure, defined as the inability to collect at least 5 Â 10 6 CD34 þ cells/kg, a goal that allows the collection of a number of SCs sufficient to perform two auto-SCT in the event a second transplantation procedure is warranted. As SC yield after a first collection set may be influenced by collection targets arbitrarily set by individual physicians and by the number of collections performed, a secondary endpoint was the SC collection efficiency, measured by the number of CD34 þ cells yielded per pheresis performed during the first set of SC collection. Logistic regression (for collection failure) and linear regression (for collection efficiency) were first used to examine the effect of baseline and treatment variables on either endpoint univariately. Variables significant at the 0.05 level were entered into multivariable models. As the collection efficiency endpoint was skewed, the variable was log-transformed before linear regression analysis. All analyses were performed using SAS 9.2 (SAS Institute, Cary, NC, USA).
RESULTS
Patients and Treatments Characteristics
A total of 378 patients was referred between 2000 and 2009 for SC collection and analyzed for this retrospective analysis. In all, 61 patients were excluded because their collection was terminated early due to poor performance status (n ¼ 1), patient refusal (n ¼ 1), incomplete collection of data records (n ¼ 18), mobilization with melphalan on a clinical trial (n ¼ 32) and mobilization with plerixafor (n ¼ 9). The baseline characteristics of the 317 remaining patients are shown in Table 1 . The median age at the time of diagnosis for all patients was 57 years (range, 26-74), with males comprising 62% of the population. At the time of diagnosis, the Patients had received a total of eight different induction regimens, including various combinations of the novel agents and older therapies. Among the 317 patients, 245 received at least one or more of the three novel agents (thalidomide, lenalidomide and bortezomib) as part of their induction therapy, whereas 72 patients did not receive any of the three aforementioned agents. These 72 patients were treated with either conventional chemotherapy or systemic corticosteroids as part of their induction therapy. For the purpose of statistical analysis, the patients were subdivided into the four groups mentioned in the Methods section and included 154 patients in group 1 (thalidomide), 76 in group 2 (lenalidomide), 127 in group 3 (bortezomib) and 72 in group 4 (none of the novel agents). The median number of induction treatment cycles before initiation of SC mobilization was 5 (range [4] [5] [6] . The median number of months between start of therapy and mobilization for all patients was 5.9 months (range, 4.5-8.3 months). The median time between completion of induction therapy and initiation of SC mobilization was 1.1 months (range: 0.7-1.6).
Predictors of SC collection failure by univariate and multivariate analyses Detailed information regarding SC collection is summarized in Table 2 . Overall, 41 patients (13%) failed to successfully mobilize a sufficient number of SCs (5 Â 10 6 CD34 þ cells/kg) with the first collection attempt. (Note: only 2.8% of patients collected less than 2 Â 10 6 CD34 þ cells/kg, the minimum CD34 þ count, which would allow them to proceed to transplant). A univariate analysis performed to identify significant risk factors for mobilization failure, showed the use of thalidomide (P ¼ 0.05), older age (P ¼ 0.002), lower platelet count (P ¼ 0.002) and the use of singleagent G-CSF for mobilization (0.0001) to be significant risk factors for mobilization failure ( Table 3 ). The use of other novel agents, the time from start of therapy to mobilization and the time from end of induction therapy to mobilization appeared to have no significant impact on the success rate of SC mobilization. By multivariate analysis using the four parameters identified by univariate analysis, only older age, lower platelet count and mobilization regimen with single-agent G-CSF retained a statistically significant negative predictor value. Exposure to lenalidomide or other novel agents before collection was not found to impact the rate of mobilization failure.
Predictors of SC collection efficiency by univariate and multivariate analysis As SC collection yield may be influenced by variable physician practices and predetermined SC collection targets, we examined the effect of the various baseline and treatment factors on collection efficiency as defined in the methods section. Univariate analyses revealed several variables associated with lower SC collection efficiency including exposure to lenalidomide, older age, male gender, previous exposure to radiation therapy, lower platelets count and the use of G-CSF as the single mobilization agent. By multivariate analysis, older age, lower platelet count and the use of G-CSF as the single mobilization agent were independently associated with lower efficiency. None of the drugs were significantly associated with poor efficiency (Table 4) .
Interestingly, using the standard cutoff of 150 000 cells/mm 3 as the lower limit of normal range for platelet count, we found 31% of patients with platelet count below 150 000 failed mobilization compared with only 11% if the platelet count was above 150 000 (P ¼ 0.004).
Subgroup analysis for patients having received lenalidomide as induction therapy Given the results of previous reports pertaining to SC mobilization failure and prior exposure to lenalidomide during induction therapy, we performed a subgroup analysis to uncover significant risk factors specifically in patients who received prior lenalidomide-based therapy. In all, 14 out of 76 patients who had been exposed to lenalidomide during induction therapy had SC collection failure (Table 5 ). None of the variables examined were significantly associated with collection failure or collection inefficiency, including the mobilization regimens.
DISCUSSION
This retrospective study found a rate of 13% SC mobilization failure (defined as the inability to collect 5 Â 10 6 CD34 þ cells/kg) following first SC collection attempt in patients with MM treated at MSKCC with a variety of induction combination regimens between 2000 and 2009, whereas only 2.8% failed to collect less than 2 Â 10 6 CD34 þ cells/kg, the minimum accepted number of SC for adequate engraftment. We analyzed baseline and treatment characteristics to identify predictors of SC collection failure. In accordance with other studies, we found by multivariate analysis, age, lower platelet count and the use of single-agent G-CSF for mobilization, to be associated with an increased risk of collection failure. These three risk factors also were found to be Factors impacting stem cell mobilization failure rate and efficiency M Pozotrigo et al associated with SC collection inefficiency, an outcome we believe to be more meaningful than the arbitrary definition of SC collection failure, as it is not biased by individual physician collection practices. Importantly, a platelet count below the normal range (o150 000 cells/mm 3 ) was associated with a significantly higher risk of SC collection failure compared to normal platelet count (Po0.004). While many other studies describe the negative impact of lenalidomide on SC mobilization, we were not able to detect a significant difference between the induction agents in this regard.
To speculate on the underlying reason for the lack of statistical significance for lenalidomide in this study, one would need to draw comparisons with previously published studies. Several publications have addressed the impact of previous exposure to lenalidomide-based therapy during induction on SC collection. Popat et al. 16 described the MD Anderson Cancer Center experience that examined 302 MM patients mobilized with G-CSF and reported a failure rate (defined as o2 million CD34 þ cells/kg collected with 4 leukophereses) as high as 25% in patients who had previously received lenalidomide-based Factors impacting stem cell mobilization failure rate and efficiency M Pozotrigo et al induction therapy in comparison with 4% in those who had not received lenalidomide. Significant risk factors for mobilization failure in that study included prior lenalidomide use as well as time from diagnosis to mobilization exceeding 1 year. Likewise, in a multicenter trial that evaluated 331 patients initially mobilized with cyclophosphamide plus G-CSF after receiving four cycles of lenalidomide-based therapy, Cavallo et al. 17 reported insufficient SC collection (defined as o4 million CD34 þ cells/kg) in 21% of patients after the first mobilization attempt, whereas after the second mobilization attempt this number was reduced to 9% of Factors impacting stem cell mobilization failure rate and efficiency M Pozotrigo et al patients. Paripati et al. 15 and Mazumder et al. 14 reporting on small series of patients mobilized with G-CSF only, found failure rates (defined as o2 million CD34 þ cells/kg) of 45% and 43%, respectively, in patients who received lenalidomide during induction therapy.
In contrast to these high rates of SC collection failure, Kumar et al. 13 detected a relatively low rate of collection failure vaguely defined as patients unable to proceed to transplantation in those previously treated with lenalidomide and mobilized with singleagent filgrastim. In this group, 3 out of 43 patients (7%) who received lenalidomide-all 3 for more than 6 months-were unable to collect sufficient SCs to proceed to transplant versus only 2 out of 199 (1%) who had received non lenalidomide-based therapies. However, they also reported a significant decrease in the total CD34 þ cells collected in an average daily collection as well as an increase in the number of phereses sessions. There was also a trend toward decreasing average CD34 þ cell collection on day 1 with increasing age, consistent with our findings. Likewise, in a retrospective analysis of 290 patients with MM, Nazha et al. 23 reported a collection failure rate (defined aso2 million CD34 þ cells/kg collected or low number of circulating SCs) of 9% among 43 patients who received lenalidomide as part of their induction therapy and were mobilized with either cyclophosphamide and G-CSF or G-CSF alone. Although the use of cyclophosphamide appeared to enhance collection, the number of patients receiving G-CSF alone was too small to draw meaningful conclusions.
Overall, the retrospective studies reported so far present very discordant results in terms of rate of SC collection failure when lenalidomide is included in the induction regimen ranging from as low as 7% to as high as 45%. These discrepancies appear to be related to the significant variance in the definition of SC collection failure as detailed above, as well as in the patient and treatment characteristics, which render comparisons between studies unfeasible. However, all studies converge to indicate a deleterious effect of lenalidomide on the ability to collect an adequate number of stem cells, regardless of the definition of SC collection failure rate. Using SC collection efficiency as done in the present study rather than an arbitrary SC collection failure for outcome measurement, we could not find a deleterious effect of lenalidomide by multivariate analysis. This observation may be attributable to the fact that the majority (86%) of patients receiving cyclophosphamide plus G-CSF for mobilization in this study and the role of cyclophosphamide in overcoming the negative effect of lenalidomide and other drugs. Indeed, in the present study, the use of single-agent G-CSF for mobilization was identified as a highly significant risk factor for both collection failure and inefficiency when the entire population of patients was analyzed. We could not identify this variable as a risk factor when specifically considering the lenalidomide population, probably because of the small number of patients mobilized with singleagent G-CSF in this group and the lack of statistical power to show such a difference.
The effect of lenalidomide on collection failure was addressed in 2009 by the International Multiple Myeloma Working Group (IMWG) who presented their recommendations for overcoming this issue. 24 Among patients who have been initially treated with fewer than four cycles of lenalidomide and are younger than 65 years, these guidelines consider singleagent G-CSF to be acceptable for mobilization. In the higher risk population, namely those who had received more than four cycles of lenalidomide, the panel recommends using cyclophosphamide plus G-CSF as the primary regimen to avoid the risk of mobilization failure. Our study appears to indirectly support this recommendation, as we were unable to show a statistically significant deleterious effect of lenalidomide in this retrospective study where most patients were mobilized with cyclophosphamide and G-CSF. In addition, we favor the use of cyclophosphamide for all patients since single agent G-CSF for mobilization was identified as independent risk factor.
In summary, we confirmed in this retrospective study, that older age, platelet count and use of single-agent G-CSF for mobilization are factors that influence SC collection failure and SC collection efficiency. We could not show that prior lenalidomide use was associated with a statistically significant higher rate of SC collection failure or lower SC collection efficiency in this population mobilized mostly with cyclophosphamide and G-CSF. These results provide further support to the recent guidelines formulated by the IMWG recommending the use of cyclophosphamide and G-CSF for SC mobilization in patients with prior exposure to lenalidomide. Recently, a study by Micallef et al. 25 examining the efficacy of plerixafor plus G-CSF among patients with MM who had prior exposure to lenalidomide yielded promising results. The possibility of utilizing plerixafor in the frontline setting may be of benefit in high-risk patients previously treated with lenalidomide. At this time however, the efficacy as well as the cost benefit of plerixafor in this setting remains to be validated by prospective randomized trials.
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